John J. Turchi
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
214
Citations
6,156
Est. group size
—
Recurring co-author estimate
Active years
36
Publishing since 1991
John J. Turchi studies how cells detect and repair damage to their DNA, focusing on proteins such as Replication Protein A (RPA) and the Ku70/80 DNA-PK complex that sense and respond to DNA breaks. A central aim of the work is to design small-molecule drugs that block these DNA damage response proteins, making cancer cells—especially BRCA1-deficient tumors and EGFR-driven lung cancers—more vulnerable to treatments like PARP inhibitors and targeted therapies.
Publication activity has grown over the decade, with a marked spike in 2023 and a sustained higher output compared with earlier years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Replication protein A protects lagging strand gaps, restricting PARP inhibitor-induced synthetic lethality in BRCA1-deficient tumors
Nucleic Acids Research · 2026
- Abstract 526: The role of ssDNA in alternative DNA DSB repair and the opportunity for therapeutic intervention.
Cancer Research · 2026
- Abstract 527: Development of novel Ku-targeted DNA-PK inhibitors for cancer therapy.
Cancer Research · 2026
- Abstract 242: Targeting the DNA damage response sensor replication protein A for first in class cancer therapy.
Cancer Research · 2026
- Abstract 7138: Acquired saruparib (AZD5305) resistance in BRCA1-deficient triple negative breast cancer is vulnerable to DNA damage response-targeted therapeutics
Cancer Research · 2026
- PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilities
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Abstract 236: Targeting DNA damage sensors (DDS) to enhance Osimertinib response in EGFR-driven cancers.
Cancer Research · 2026
- Targeting DNA damage sensors for cancer therapy
DNA repair · 2025
- Design, Synthesis, and Structure–Activity Relationship Studies of 4-substituted Phenylpyrazolidinone Derivatives as Potent Ku70/80 Targeted DNA-PK Inhibitors
ChemRxiv · 2025
- Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibition
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Structure-Based Design and Development of 2-Oxindole Derivatives as Next Generation Ku-DNA Binding Inhibitors (Ku-DBi’s) for Cancer Therapy.
ChemRxiv · 2025
- Design, synthesis, and structure–activity relationship studies of 4-substituted phenylpyrazolidinone derivatives as potent Ku70/80 targeted DNA-PK inhibitors
RSC Medicinal Chemistry · 2025
- Analyzing DNA-Protein Interactions with Streptavidin-Based Biolayer Interferometry
Journal of Visualized Experiments · 2025
- Biochemical impact of p300-mediated acetylation of replication protein A: Implications for DNA metabolic pathway choice
Journal of Biological Chemistry · 2025
- Potentiation of EGFR mutant lung cancer treatment targeting replication stress
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Cancer Research×19
- bioRxiv (Cold Spring Harbor Laboratory)×7
- PMC×4
- Molecular Cancer Therapeutics×4
- European Journal of Cancer×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile